Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

被引：23

作者：

Gowda, Lohith ^{[1
]}

Shah, Mithun ^{[2
]}

Badar, Ifra ^{[3
]}

Bashir, Qaiser ^{[3
]}

Shah, Nina ^{[4
]}

Patel, Krina ^{[5
]}

Kanagal-Shamanna, Rashmi ^{[6
]}

Mehta, Rohtesh ^{[3
]}

Weber, Donna M. ^{[5
]}

Lee, Hans C. ^{[5
]}

Manasanch, Elisabet E. ^{[5
]}

Shah, Abdul ^{[3
]}

Thomas, Sheeba K. ^{[5
]}

Parmar, Simrit ^{[3
]}

Nieto, Yago ^{[3
]}

Orlowski, Robert Z. ^{[5
]}

Champlin, Richard ^{[3
]}

Qazilbash, Muzaffar H. ^{[3
]}

机构：

[1] Yale Sch Med, Div Hematol, New Haven, CT 06511 USA

[2] Mayo Clin, Div Hematol Malignancies, Rochester, MN 55905 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant, Houston, TX 77030 USA

[4] Univ Calif San Francisco, Div Hematol, San Francisco, CA 94143 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 07期

关键词：

DEXAMETHASONE; LENALIDOMIDE; MYELOMA; BORTEZOMIB; CONSOLIDATION; SURVIVAL;

D O I：

10.1038/s41409-018-0392-1

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.

引用

页码：1089 / 1093

页数：5

共 14 条

[1] Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia
Benson, Don M., Jr.
Smith, Megan K.
[J]. LEUKEMIA & LYMPHOMA, 2007, 48 (07) : 1423 - 1425
[2] Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
D'Arena, G.
Valentini, C. G.
Pietrantuono, G.
Guariglia, R.
Martorelli, M. C.
Mansueto, G.
Villani, O.
Onofrillo, D.
Falcone, A.
Specchia, G.
Semenzato, G.
Di Renzo, N.
Mastrullo, L.
Venditti, A.
Ferrara, F.
Palumbo, A.
Pagano, L.
Musto, P.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1499 - 1502
[3] Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
Guglielmelli, Tommasina
Merlini, Roberta
Giugliano, Emilia
Saglio, Giuseppe
[J]. JOURNAL OF ONCOLOGY, 2009, 2009
[4] Jakubowiak A, 2015, HAEMATOLOGICA, V100, P312
[5] Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience
Lebovic, Daniel
Zhang, Ling
Alsina, Melissa
Nishihori, Taiga
Shain, Kenneth H.
Sullivan, Daniel
Ochoa-Bayona, Jose L.
Kharfan-Dabaja, Mohamed A.
Baz, Rachid
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06) : 507 - 511
[6] Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research
Mahindra, A.
Kalaycio, M. E.
Vela-Ojeda, J.
Vesole, D. H.
Zhang, M-J
Li, P.
Berenson, J. R.
Bird, J. M.
Dispenzieri, A.
Gajewski, J. L.
Gale, R. P.
Holmberg, L.
Kumar, S.
Kyle, R. A.
Lazarus, H. M.
Lonial, S.
Mikhael, J.
Milone, G. A.
Munker, R.
Nath, R.
Saccaro, S.
To, L. Bik
Vogl, D. T.
Wirk, B.
Hari, P.
[J]. LEUKEMIA, 2012, 26 (05) : 1091 - 1097
[7] Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, Philip L.
Owzar, Kouros
Hofmeister, Craig C.
Hurd, David D.
Hassoun, Hani
Richardson, Paul G.
Giralt, Sergio
Stadtmauer, Edward A.
Weisdorf, Daniel J.
Vij, Ravi
Moreb, Jan S.
Callander, Natalie Scott
Van Besien, Koen
Gentile, Teresa
Isola, Luis
Maziarz, Richard T.
Gabriel, Don A.
Bashey, Asad
Landau, Heather
Martin, Thomas
Qazilbash, Muzaffar H.
Levitan, Denise
McClune, Brian
Schlossman, Robert
Hars, Vera
Postiglione, John
Jiang, Chen
Bennett, Elizabeth
Barry, Susan
Bressler, Linda
Kelly, Michael
Seiler, Michele
Rosenbaum, Cara
Hari, Parameswaran
Pasquini, Marcelo C.
Horowitz, Mary M.
Shea, Thomas C.
Devine, Steven M.
Anderson, Kenneth C.
Linker, Charles
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) : 1770 - 1781
[8] Primary plasma cell leukemia in the era of new drugs: Has something changed?
Musto, Pellegrino
Pagano, Livio
Petrucci, Maria Teresa
Morabito, Fortunato
Caravita, Tommaso
Di Raimondo, Francesco
Baldini, Luca
Tosi, Patrizia
Bringhen, Sara
Offidani, Massimo
Omede, Paola
Neri, Antonino
D'Auria, Fiorella
Bochicchio, Giovanni Battista
Cavo, Michele
Boccadoro, Mario
Palumbo, Antonio
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 (02) : 141 - 149
[9] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
Nooka, A. K.
Kaufman, J. L.
Muppidi, S.
Langston, A.
Heffner, L. T.
Gleason, C.
Casbourne, D.
Saxe, D.
Boise, L. H.
Lonial, S.
[J]. LEUKEMIA, 2014, 28 (03) : 690 - 693
[10] International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Palumbo, Antonio
Rajkumar, S. Vincent
San Miguel, Jesus F.
Larocca, Alessandra
Niesvizky, Ruben
Morgan, Gareth
Landgren, Ola
Hajek, Roman
Einsele, Hermann
Anderson, Kenneth C.
Dimopoulos, Meletios A.
Richardson, Paul G.
Cavo, Michele
Spencer, Andrew
Stewart, A. Keith
Shimizu, Kazuyuki
Lonial, Sagar
Sonneveld, Pieter
Durie, Brian G. M.
Moreau, Philippe
Orlowski, Robert Z.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) : 587 - +

← 1 2 →